Picture EBD Group Global Partnering Four Events One Price 650x80
Organisation › Details

Repertoire Immune Medicines (Group)

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unlock and direct the remarkable power of the human immune system to prevent or treat cancer, as well as autoimmune disorders, infectious diseases, and other serious diseases. The company’s repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. Repertoire scientists created and developed the DECODE and DEPLOY suite of technologies, which allow in-depth characterization of TCR-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines. Repertoire Immune Medicines was formed in December 2019 by combining two Flagship Pioneering companies to create a fully integrated immune medicines company. From its sites in Cambridge, Massachusetts, and Zurich, Switzerland, Repertoire’s team of more than 120 is creating a new category of immune medicines enabled from its DECODE discovery platform and DEPLOY development engine. The company’s first product in the clinic is a novel multiclonal T cell therapy consisting of naïve, rare T cells derived from the peripheral blood, activated against a curated set of antigens, and armed with a proprietary cytokine payload. Repertoire is in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, Repertoire is using its proprietary platform to discover novel epitopes and TCRs from patients with type 1 diabetes. The company is also using its DECODE platform to discover infectious disease antigens and responding T cell clones. *


Period Start 2019-12-01 merged
Product Industry BIOTECH
Person Person Cox, John G. (Repertoire Immune Medicines 202104 CEO formerly Bioverativ 201801 CEO)
Region Region Cambridge, MA
  Country United States (USA)
  Street One Kendall Square
  City 02139 Cambridge, MA
    Address record changed: 2021-04-13
Basic data Employees D: 101 to 500 (2021-04-13)
    * Document for �About Section�: Repertoire Immune Medicines. (4/13/21). "Press Release: Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets". Cambridge, MA.
Record changed: 2021-04-13


Picture Excelya CRO Your Trial Across Europe 650x80px

More documents for Repertoire Immune Medicines (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Global Partnering Four Events One Price 650x80

» top